A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients
The purpose of this study is to compare the safety and effectiveness of two anti-HIV drug
combinations when given to HIV-infected patients who have never been treated with anti-HIV
drugs. One drug combination is stavudine (d4T) plus didanosine (ddI) plus Crixivan. The
other combination is Retrovir (AZT) plus Epivir (3TC) plus Crixivan.
A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection
To assess the safety and tolerance of multiple oral doses of 141W94 alone, in combination
with 1592U89, and in combination with Retrovir and Epivir, administered to patients with HIV
infection as measured by the development of clinical adverse experiences and laboratory test
abnormalities. To determine the steady-state pharmacokinetics of 141W94 alone and in
combination with 1592U89 after multiple oral dosing. To obtain preliminary evidence of
antiretroviral activity of 141W94 alone and in combination with 1592U89, the antiretroviral
effect of combined Retrovir/Epivir and the antiretroviral effect of 141W94 when added to
Retrovir/Epivir or to 1592U89/Retrovir/Epivir.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.